- CDC News
- Adult Immunization
- Hepatology
- Rare Disorders
- Pediatric Immunization
- Weight Management
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Kidney Disease
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Orthopedics
- Obesity Medicine
- Rheumatology
- Technology
- Oncology
- Nephrology
- Neurology
- Pulmonology
Expanding the Obesity Treatment Toolbox: The Promise of Dual-Action Medications
Michael Crotty, MD, an expert in obesity medicine, discusses GLP-1RAs in the context of weight loss, including the novel dual agonist survodutide.
Glucagon-like peptide-1 (GLP-1) receptor agonists have become a prominent topic in professional meetings, medical research, and mainstream media. Initially approved for managing type 2 diabetes, GLP-1RAs are now widely used for weight management in individuals with obesity or overweight.
One promising medication in this class currently under investigation is survodutide, a dual GLP-1RA/glucagon receptor (GCGR) agonist. Preliminary data suggest that this dual agonist may benefit people with obesity or overweight and metabolic conditions, including metabolic dysfunction-associated steatohepatitis (MASH). As survodutide and other new therapies emerge, Michael Crotty, MD, a general practitioner who specializes in obesity medicine, anticipates they will further expand the obesity treatment toolbox. In an interview with Patient Care Online, Dr Crotty also emphasized the need for a comprehensive treatment approach, including lifestyle and behavioral interventions, to complement the use of medications. Watch the video above for more details.
Dr Crotty is also the co-founder and clinical lead of My Best Weight in Dublin, Ireland.
